Bladder Regeneration via MSC and CD34+ Cell Co-Transplantation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for bladder regeneration, such as bladder augmentation enterocystoplasty, are associated with significant side effects and obstacles, including electrolyte imbalance, infection, stone formation, and the potential for malignant transformation, due to the use of bowel segments, and have challenges in recreating functional bladder tissue ex vivo.
Innovation Solution
The use of populations of bone marrow mesenchymal stem cells (MSCs) and CD34+ hematopoietic stem/progenitor cells (HSPCs), co-administered with a scaffold, to enhance bladder tissue regeneration, with specific cell populations and methods for isolation and co-administration to improve vascularization and urothelium regeneration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bladder augmentation enterocystoplasty is performed using bowel segments, then bladder capacity and physiological parameters are improved, but side effects such as electrolyte imbalance, infection, stone formation, and malignant transformation risk increase
Solution Approach 1:
The invention extracts and eliminates the harmful bowel segment material from the augmentation procedure, replacing it with acellular matrix and stem cell populations. This removes the source of electrolyte imbalance, infection, and malignant transformation while preserving the bladder augmentation function.
Solution Approach 2:
The invention changes the fundamental parameters of the augmentation material from living bowel tissue to acellular matrix with controlled stem cell populations. This parameter change eliminates the metabolic and immunological complications of bowel tissue while maintaining structural and functional benefits.
2Reliability
If attempts are made to recreate functional bladder tissue ex vivo, then tissue regeneration is improved, but materials design issues and cellular incompatibilities arise
Solution Approach 1:
The invention introduces an acellular matrix as an intermediary scaffold that mediates between the host tissue environment and the transplanted stem cells. This intermediary provides structural support and biochemical cues while eliminating direct cellular incompatibilities and simplifying materials design.
Solution Approach 2:
The invention segments the tissue regeneration process into distinct functional components: the acellular matrix provides structural framework and biochemical signaling, while separate stem cell populations (MSCs and CD34+ HSPCs) provide regenerative and vascularization functions. This segmentation allows optimization of each component independently.
Data Source
AI summary
Provided herein are populations of bone marrow mesenchymal stem cells (MSCs) and CD34+ hematopoietic stem/progenitor cells (HSPCs), and methods of isolation and co-administration thereof. In particular, cell populations and methods of co-administration thereof are provided for enhancing tissue (e.g., bladder) regeneration.